02934nam 2200661 a 450 991081206820332120200520144314.00-309-17816-91-282-08355-497866120835560-309-12089-6(CKB)1000000000785689(OCoLC)726823396(CaPaEBR)ebrary10286191(SSID)ssj0000114554(PQKBManifestationID)11129889(PQKBTitleCode)TC0000114554(PQKBWorkID)10125386(PQKB)11547321(MiAaPQ)EBC3378464(Au-PeEL)EBL3378464(CaPaEBR)ebr10286191(CaONFJC)MIL208355(OCoLC)923280041(EXLCZ)99100000000078568920090925d2009 uy 0engurcn|||||||||txtccrBreakthrough business models drug development for rare and neglected diseases and individualized therapies : workshop summary /Theresa Wizemann, Sally Robinson, and Robert Giffin ; Forum on Health Sciences Policy, Institute of Medicine of the National Academies1st ed.Washington, D.C. National Academies Press20091 online resource (149 p.)Bibliographic Level Mode of Issuance: Monograph0-309-12088-8 Includes bibliographical references (p. 104-105).Introduction and overview -- Current model for financing drug development : from concept through approval -- The Food and Drug Administration's Orphan Drug Program -- Diverse funding models -- Strategies for facilitating sharing of research materials and data -- Strategies of navigation intellectual property -- Strategies for facilitating clinical trials -- Summary."The Institute of Medicine's Forum on Drug Discovery, Development, and Translation held a public workshop on June 23, 2008, titled "Breakthrough Business Models: Drug Development for Rare and Neglected Diseases and Individualized Therapies." The purpose of the workshop was to explore innovative strategies for orphan drug development."--P. 3.Orphan drugsGovernment policyUnited StatesPharmaceutical policyUnited StatesDrugsDesignUnited StatesOrphan drugsGovernment policyPharmaceutical policyDrugsDesign615/.19Wizemann Theresa M890630Robinson Sally620917Giffin Robert B1653478Institute of Medicine (U.S.).Forum on Drug Discovery, Development, and Translation.MiAaPQMiAaPQMiAaPQBOOK9910812068203321Breakthrough business models4039330UNINA